Navigation Links
Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA(TM) in the U.S.
Date:8/26/2009

CHADDS FORD, Pa., Aug. 26 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.

FORTESTA, a patented 2 percent testosterone transdermal gel for testosterone replacement therapy in male hypogonadism, utilizes a metered dose delivery system designed to permit accurate dose adjustment to individual patient requirements. This product is in registration in the U.S., where the Food and Drug Administration (FDA) is currently reviewing ProStrakan's New Drug Application submission.

Under the terms of the agreement, Endo Pharmaceuticals has agreed to make an upfront payment to ProStrakan of $10 million, with the potential for up to $40 million more in milestone payments by the end of 2010 for regulatory approval and the achievement of certain commercial milestones. Endo Pharmaceuticals has also agreed to pay ProStrakan an additional $160 million upon the achievement of certain sales targets. ProStrakan will exclusively supply FORTESTA to Endo Pharmaceuticals in the U.S. for an undisclosed supply price.

"We are committed to advancing men's health with effective new medicines. Being in a position to potentially offer this treatment, alongside our new long-acting injectable testosterone product, will help fill an important gap in testosterone replacement," said David Holveck, president and chief executive officer of Endo Pharmaceuticals. "This treatment option is synergistic with our recent therapeutic expansion and strengthens our portfolio in urology and endocrinology."

About FORTESTA

FORTESTA (branded variously as Tostran, Tostrex and Itnogen) is marketed across Europe by ProStrakan's own, in-house sales forces and is out-licensed by ProStrakan to Bayer Schering Pharma (BSP) in 147 countries, in many of which FORTESTA is planned to be promoted alongside Nebido((R)), which is Endo Pharmaceuticals' testosterone undecanoate product, or long-acting injectable, currently under regulatory review with the FDA in the United States.

About Hypogonadism

Hypogonadism, or low testosterone, is a common yet largely under-recognized and under-treated condition. An estimated 13.8 million American men have testosterone levels characterized as below normal (testosterone <300ng/dl). Yet despite this high prevalence, only about 9 percent of men with low testosterone are treated with testosterone replacement therapy.

About ProStrakan

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office is located in Galashiels, Scotland. The company's development capabilities are centered in Galashiels and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the U.K., U.S., France, Germany, Spain and other EU countries. www.prostrakan.com

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, overactive bladder, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM((R)), a topical patch to relieve the pain of postherpetic neuralgia; Percocet((R)) and Percodan((R)) tablets for the relief of moderate-to-moderately severe pain; FROVA((R)) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA((R) )tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA((R)) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; Voltaren((R) )Gel, which is owned and licensed by Novartis AG, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as those of the hands and the knees; SANCTURA((R)) and its XR version for treatment of overactive bladder; VANTAS((R)) for the palliative treatment of advanced prostate cancer; and SUPPRELIN((R)) LA for the treatment of early onset puberty in children. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, endocrinology and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the company's financial position, results of operations, market position, product development and business strategy, as well as estimates of future net sales, future expenses, future net income and future earnings per share. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in this press release. These factors include, but are not limited to those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS" in our annual report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on March 2, 2009. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Endo Pharmaceuticals Announces Cash Tender Offer for Any and All Outstanding Ledgemont PhaRMA(SM) Secured 16% Notes
2. Robin Leedy & Associates Wins Social Media Program For Union Springs Pharmaceuticals
3. Adamas Pharmaceuticals Expands Management Team; Names Michael D. Coffee and Amy K. Patick to Executive Positions
4. Raptor Pharmaceuticals Raises $5 Million
5. Cumberland Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 27, 2009
6. The Rossbacher Law Firm, Hagens Berman Sobol Shapiro LLP, Wilentz Goldman & Spitzer, P.A., Reed Smith LLP and Thompson Hine LLP, Announce the Proposed Settlement of a Class Action Lawsuit Concerning Estratest and Solvay Pharmaceuticals, Inc.
7. NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting
8. Warner Chilcott Acquires P&Gs Global Pharmaceuticals Business
9. Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN)
10. Sound Pharmaceuticals Receives an Office of Naval Research Award for Its Hearing Loss Research and Development
11. Adamas Pharmaceuticals Raises $40 Million in Series D Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , ... February 12, 2016 , ... Fitbody Personal Training ... a fun and exciting way to get fit and healthy. Located in Phoenixville, PA, ... dates for a class designed for horseback riders who want to lose weight and ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... participated in the American Osteopathic Association’s (AOA) Match Program Tuesday, February 9, taking ... Program places students into osteopathic graduate medical education positions across the country. Of ...
(Date:2/11/2016)... ... February 12, 2016 , ... The Journal of Pain Research ... in 2013. The SJR uses data taken from the Scopus database (Elsevier B.V.) and ... of citations received by the journal over a three year period and also the ...
(Date:2/11/2016)... ... 2016 , ... Hall Integrative Health and Chiropractic, PC which ... grand openings in March. All seven practices are set to start accepting patients ... diabetes possible? According to this 2011 CNN article it is possible: http://www.cnn.com/2011/HEALTH/01/28/reverse.diabetes/ ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... upcoming Feb. 23 webinar, “Intel’s Direct-to-Employee Benefit Model: A Case Study for Plans ... Catholic health care system that’s partnering with Intel on value-based health benefits program ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... PORTLAND, Ore. , Feb. 11, 2016 ... to announce the acquisition of SolutionsRx, a full-service 340B ... hospitals. Along with providing traditional contract pharmacy services, SolutionsRx ... assist clients in navigating the complex 340B regulatory environment. ... Wellpartner. --> James R. Love , CEO ...
(Date:2/11/2016)... , Feb. 11, 2016  Attending college is ... those with type 1 diabetes, the journey can be ... schedules, assignments and campus activities, they also manage the ... top of that, many are living away from home ... (Foundation) Lilly Diabetes Tomorrow,s Leaders Scholarship with $100,000 ...
(Date:2/11/2016)... -- Jeffrey Zucker , vice president of ... at this year,s Summit for Clinical Operations Executives (SCOPE), being ... Miami, FL. Zucker will discuss how sponsors can ... SCOPE,s "Improving Site Study Activation and Performance" portion of the ... at 11:05 a.m. --> --> ...
Breaking Medicine Technology: